Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Efruxifermin in Non-Cirrhotic NASH/MASH With Fibrosis
2023-505141-48-00Phase 3Authorised
- Sponsor
- Akero Therapeutics
- Start
- Dec 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis comparing Efruxifermin with Placebo (2 arms). Planned start Dec 2023; status: authorised.
02
Drugs
efruxifermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on 2023-505141-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505141-48-00.